Theravance Biopharma, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Theravance Biopharma, Inc. (TBPH) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -4.07% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-23
- Theravance Biopharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -4.07%.
- Theravance Biopharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2017 was 2.79%, a 105.15% increase from fiscal 2016.
- Theravance Biopharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2016 was 1.36%, a 130.51% increase from fiscal 2015.
- Theravance Biopharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2015 was 0.59%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -4.07% 10-K · filed 2026-03-23 | |
| 2017-12-31 | 2.79% 10-K · filed 2018-02-28 | |
| 2016-12-31 | 1.36% 10-K · filed 2018-02-28 | |
| 2015-12-31 | 0.59% 10-K · filed 2018-02-28 | -0.50% 10-K · filed 2016-03-11 |
| 2014-12-31 | -0.10% 10-K · filed 2017-03-01 | -0.35% 10-K · filed 2015-03-13 |
| 2013-12-31 | -0.98% 10-K · filed 2016-03-11 | -1.19% 10-K · filed 2015-03-13 |
| 2012-12-31 | 0.04% 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |